Can PP-01 become the first approved cannabis withdrawal treatment? PleoPharma’s Phase 3 test begins
PleoPharma secures $6.5M NIDA funding as a 420-patient Phase 3 trial tests PP-01 for cannabis withdrawal in adults with cannabis use disorder.
Pharma & Biotech
Pharma & Biotech
How Sparian Biosciences’ Phase 1 launch of SBS-147 could reshape the non-opioid pain treatment landscape
Discover how Sparian Biosciences’ SBS-147 Phase 1 launch could change the race for safer non-opioid pain treatments. Read the full analysis.